(CME). Lymphocytes also were only slightly hyporesponsive to mitogens. Reconstitution of the CMRV with the CME of phase I whole cells restored the immunopathological reactions that were associated with the phase I whole cell vaccine (WCV). The CMRV was more mitogenic than the WCV for lymphocytes from mice injected with saline. Lymphocytes from phase I WCV-injected mice were negatively modulated with nontoxic concentrations of homologous WCV or CMRV. Lymphocytes from phase I CMRV-injected mice were only slightly hyporesponsive to mitogens and were significantly stimulated by antigens of either WCV or CMRV as recall antigens. Vaccination of mice with 100 ,ug of CMRV, CME, or WCV provided 80, 0, or 50% protection, respectively, against a lethal intraperitoneal challenge with viable phase I C. burnetii. The epitopes which induce immunological hyporesponsiveness, negative modulation, and the death of lymphocytes were fractionated into the CMRV and CME. The CMRV provides at least one of the determinants which induce immunosuppression, whereas CME contains specific or nonspecific components or both. Collectively, these results show that the CMRV may be a potential candidate to replace the WCV currently used for human vaccination.
Infection of individuals with phase I Coxiella burnetii, the etiological agent of Q fever, results in the development of serum antibodies and of cell-mediated immunity, which are readily detectable by various in vivo and in vitro assays. Protection against natural or experimentally induced infection is obtained by vaccination with suspensions of killed phase I whole-cell vaccines (WCV) which induce immunopathological reactions in humans and animals (5, 27) . Previous studies on the safety and efficacy of WCV have centered around a determination of the acceptable dosage of vaccine based on side effects, on antibody conversion rate (29) , and on the detection of cell-mediated immunity with a delayed-type skin test (3, 20) or in vitro lymphocyte proliferation assay (14) . Adverse reactions obtained during vaccine trials have prevented the widespread and unconditional use of phase I WCV. Attempts to remove components which induce adverse reactions have met with limited success because partially purified phase I antigens obtained by various organic or aqueous solvent extractions were effective immunogens only when used with adjuvants (for a review see reference 5) . Thus, the relationship between phase I WCV and immunogenic fractions which induce deleterious tissue reactions, delayed-type hypersensitivity, in vitro lymphocyte proliferation, and resistance to infection is not known.
Recent studies have shown that immunization of C57 BL/10 ScN endotoxin-nonresponder mice with phase I WCV of C. burnetii induced immunopathological reactions (9, 32) . Immunization with phase I WCV induced a time-and dosage-dependent lymphocyte unresponsiveness which correlated with the appearance of hepatomegaly and splenomegaly and with death of the mice (32) . Concurrently, generalized nonspecific splenic and lymph node lymphocyte hyporesponsiveness was developed to concanavalin A (ConA), phytohemagglutinin-P (PHA), and pokewded mitogens (PWM) (9) . Splenic and lymph node lymphocytes from immunized mice were down regulated below normal control levels by specific recall antigen. In these studies cellular expression of negative modulation was a property of phase I C. burnetii since phase II cells were not effective in the induction of lymphocyte unresponsiveness (9) . Components of the phase I WCV which were not required for protective efficacy were successfully extracted with chloroform-methanol (32) . In and extracted components (CME).
Reconstitution of CMR with CME was performed by suspending CMR (3.6 mg) with CME (1 mg) in chloroformmethanol (4:1) at a ratio of approximately four parts of CMR and one part of CME. The suspension was treated in an ultrasonic cleaner (model 8845-30; Cole-Parmer) for 5 min and incubated at room temperature for 48 h. This suspension was dried under a stream of nitrogen, and the residue was suspended in saline or tissue culture medium with the aid of an ultrasonic cleaner. Another reconsitution was carried out with 1 mg of CME in chloroform-methanol (4:1), but the CME sample was dried under a stream of nitrogen before adding the CMR suspended in saline. Resuspension was carried out in an ultrasonic cleaner for 5 min.
Chemical analyses of the WCV, CMRV, and CME. Amino acids, total phosphorus (21), total neutral sugars (10), 3- deoxy-D-manno-octulosonic acid (KDO)-like components (25) , and total fatty acids were analyzed as previously described (1) .
Immunization. C57BL/10 ScN endotoxin-nonresponder (8, 23) mice (Harlan Sprague-Dawley, Inc., Indianapolis, Ind.) were injected intraperitoneally (i.p.) in groups of 3 to 10 mice with 0.5 ml of saline containing various concentrations of either WCV, CMRV, CME, or CMRV reconstituted with CME.
Immunological assays. Graded doses of vaccine preparations were evaluated for the induction of pathological responses and immunity as follows: the measurement of hepatosplenomegaly (32) ; the induction of immunosuppression based on the incorporation of [3H]TdR (specific activity, 5 Ci/mmol; Amersham Corp., Arlington Heights, Ill.) by splenic lymphocytes in response to mitogens and recall antigens; and the induction of immunity based on splenic lymphocyte responses to recall antigens (9) , production of phases I and II antibodies (anti-phase I and anti-phase II) (11) , and protection against a lethal i.p. challenge dose of phase I C. burnetii (32) .
Responses (13, 34) .
RESULTS
Chemical compositions of fractions. Fractionation of the WCV into CMR and CME resulted in the recovery of roughly 80% as CMR and 20% as CME (32) . Analyses of total protein by amino acid composition of each fraction indicated that the CMR contained about 16% less protein than the WCV, and the CME contained only 0.4% protein (Table 1) . Phosphate, neutral sugars, and fatty acids were present in each fraction. Phosphorous concentrations were highest in whole cells but were roughly equivalent in the CMR and CME fractions. Neutral sugar concentrations were greatest in CMR and least in CME. Concentrations of KDO-like compounds were greatest in the WCV and least in CME. The major portion of the fatty acids were fractionated into the CME. But the percentage of the total fatty acids represented by the branched chain fatty acids in each fraction was very similar.
Relative effectiveness of WCV, CMRV, and CME in eliciting splenomegaly, specific antibody, and lymphocyte responsiveness. The effects of a single i.p. injection of saline or of 10, 100, and 1,000 pug of either WCV or CMRV on spleen weight, specific antibody response, and mitogenic activity were evaluated in C57BL/10 ScN mice. Animals treated with WCV showed a significant spleen weight increase which was dependent on time and dosage (Fig. 1A) . Increase in spleen weight was detected by day 3 postinjection and reached a maximum by day 21 for the 10-and 1,000-,ug dosage and days 14 to 21 for the 100-,ug dosage. Transient splenomegaly was noted for the 10-and 100-p,g dosage, whereas the 1,000-,ug dosage produced splenomegaly throughout the 35-day experimental period. Animals injected with CMRV ( Fig. 1B) and with 100 ,ug of CME (data not shown) showed no splenomegaly.
The temporal sequences of anti-phase I and anti-phase II antibodies after the i.p. injections of saline or of 10, 100, and 1,000 ,ug of WCV and CMRV were compared ( Table 2 ). The anti-phase II response was detected on day 3 postinjection at all three dosages and continued to increase until 35 days postinjection. Anti-phase I activity was detected by days 7 and 14 postinjection of either 100 or 1,000 ,ug of WCV and CMRV, and specific anti-phase I activity continued to in- Elicitation of anti-phase I and anti-phase II activities with WCV and CMRV was related to the persistence of antigen in the spleens of injected mice. Clearance of WCV antigen by mice was less effective since antigen was detected in spleen impression smears 35 days postinjection, whereas CMRV antigen was not detected (data not shown).
Responses of splenic lymphocytes from vaccinated mice to the mitogens ConA, PHA, and PWM were tested in microplate cultures. Mice receiving 100 ,ug of CMRV showed a transient suppression of the mitogenic activity of ConA and PHA on days 3 and 7, but the mitogenic activity returned to normal values by day 14 (Fig. 2, ConA and  PHA) . Suppression of the mitogenic activity of PWM was not detected (Fig. 2, PWM) . The transient suppression observed with this CMRV preparation was attributed to inadequate chloroform-methanol extraction of the WCV. Extraction of WCV five times with chloroform-methanol resulted in a CMRV which did not induce marked suppression on day 4 postinjection ( Table 3) .
Mitogen-induced lymphocyte proliferation of normal, untreated spleen cell suspensions from saline-injected mice gave SI for ConA, PHA, and PWM of 43, 9, and 19, respectively (Table 4 ). Lymphocytes from mice receiving 100 ,ug of WCV gave SI for ConA, PHA, and PWM of 8, 2, and 6, respectively. Lymphocytes from mice receiving 100 ,ug of CMRV gave SI for ConA, PHA, and PWM of 45, 9, and 17, respectively. Thus, injection of mice with CMRV did not suppress the proliferation response of lymphocytes to mitogens; whereas WCV produced a persistent suppression of lymphocyte activity to ConA, PHA, and PWM by 81, 78, and 68%, respectively. This persistent suppression of lymphocyte activity elicited by WCV seemed to correlate with the capacity of WCV to induce splenomegaly (Fig. 1A) . Injection of CMRV, on the other hand, resulted in enhancement of lymphocyte activity to ConA (-5%), a slight suppression of lymphocyte activity to PWM (11%), and no effect on lymphocyte activity to PHA.
Effect of WCV and CMRV on lymphocyte responses. Mitogenic activity of WCV and CMRV was tested with normal splenic lymphocyte suspensions (Fig. 3) . A dose-response curve of WCV or CMRV indicated that maximal mitogenic activity was obtained with a dosage of between 50 and lOC ,ug of WCV per ml, and a plateau was achieved at a dosage of 100 jig of CMRV per ml. Thus, CMRV was roughly threefold more mitogenic than the WCV based on weight and chemical composition (Table 1 ). These data suggest that either WCV was less mitogenic than CMRV or that WCV contained components that decreased the activity or viability of mouse splenic lymphocytes.
Lymphocytes from normal and immunized mice were tested in an antigenic lymphocyte proliferation assay (Table  5 ). Mice were immunized with 100 ,ug of WCV or CMRV, and in vitro cultures of splenic lymphocytes were mixed with 0, 5, 50, and 500 ,ug of the respective antigens per ml. The WCV and CMRV at 5 and 50 ,ug/ml, respectively, were mitogenic for normal splenic lymphocytes (Table 5) . Negative modulation of splenic lymphocyte responses to antigen was obtained with WCV-injected mice, whereas antigeninduced lymphocyte proliferation was obtained with CMRVinjected mice ( Reconstitution of CMRV with CME. Since both CMRV and CME injected separately did not induce splenomegaly or suppression of lymphocyte activity, we tested the hypothesis that reconstitution of CMRV with CME would induce both immunopathological responses and suppression of lymphocyte activity. Reconstitution of CMRV with CME in phosphate-buffered saline did not induce marked splenomegaly or suppression of lymphocyte activity (data not shown), whereas reconstitution in chloroform-methanol induced marked splenomegaly and suppression of lymphocyte activity ( Table 6 ). Injection of CMRV produced enhanced mitogenic activity of lymphocytes without splenomegaly. Injection of CME alone induced neither splenomegaly nor antigenic negative modulation of splenic lymphocytes (data not shown), but it did induce slight mitogenic lymphocyte hyporesponsiveness (Table 6) .
Protection against a lethal challenge dose of viable phase I C. burnetii cells. The protective efficacy of a dosage of 100 ,ug of either WCV, CMRV, or CME was tested in mice (Table  7 ). Immunized mice were challenged i.p. 14 days postinjection with phase I C. burnetii at a dosage of 7 x 1010 PFU per mouse (32, 34) . WCV protected 50% of the mice, CMRV protected 80% of the mice, and CME was not efficacious. Multiple injections with CMRV were therapeutic since they gave partial protection against the immunopathological changes associated with prior or subsequent injections of (3, 20, 29) , guinea pigs (2), and mice (9, 32) . The chemical composition of the subfractions of C. burnetii responsible for these immunopathological properties has not been characterized. Our interest in subfractions of C. burnetii that elicit protective immunity without inducing deleterious tissue reactions follows from a previous study which showed that CMRV was efficacious in mice (32) . In the present study, the immunomodulatory activities of WCV, CMRV, and CME were compared. The results indicated that i.p. injection of mice with CMRV did not induce suppression of mitogenic or antigenic lymphocyte proliferation. The suppressive activity of phase I WCV in C57BL/10 ScN mice (9) results in mitogenic hyporesponsiveness and antigenic-negative modulation of splenic lymphocytes, affecting the in vitro replication of both B and T cells. The negative regulatory activity of phase I C. burnetii on previously sensitized splenic lymphocytes suggests that WCV was able to directly regulate lymphocyte activity. Evaluation of the immunogenic potential of CMRV indicated that the immunosuppressive and pathologic activity was successfully extracted by chloroform-methanol (Fig. 2 , Tables 3 and 4), but these activities were reconstituted by recombining CMRV with CME (Table 6 ). In addition, CMRV was more mitogenic for normal splenic lymphocytes than WCV was on a weight basis (Fig. 3) . It is noteworthy that the extraction of adjuvant-active materials by chloroform-methanol did not reduce the prophylactic efficacy of the CMRV, which was equal to or slightly greater than that of the WCV ( Table 7) .
The suppressive activity exhibited by phase I C. burnetii vaccine may be a useful correlate of pathologic behavior during C. burnetii infection. Recent studies have shown that murine lymphocytes from infected animals are suppressed (9) . Moreover, studies with peripheral blood lymphocytes from human Q fever patients with clinical signs of primary, hepatic, and endocarditic involvement suggest that suppressor cell activity either plays a role in the development or is a result of chronic Q fever (17) . In those studies, the induction of suppression was antigen specific, but the suppressor mechanism was antigen nonspecific (17) (18) (19) . Thus, antigenspecific lymphocyte unresponsiveness was apparently in (17, 26) . The highest levels of antibody occur in chronic disease, suggesting that, in addition to a minor role in protection, antibodies may affect pathogenesis in the form of immune complexes which have been detected in naturally infected humans and in experimentally infected guinea pigs (22, 33) . Regardless of the role of antibody, the selective immunological unresponsiveness to antigens of C. burnetii may provide a biological advantage so that the microorganisms survive in the granuloma or vegetations on aortic and mitral valves (26) . Two isolates from heart valve tissue (26) infected and produced lesions in C57BL/10 ScN mice. However, no marked changes in spleen weight or lymphocyte responsiveness were observed (unpublished results). These results were contrary to those produced by the C. burnetii Ohio strain, phase I, laboratory-adapted strain.
Examples of immunomodulation by phase I WCV are the granulomatous hypersensitivity noted in liver, bone marrow, and dermis (2, 30, 31) . Recently, Ascher et al. (2) induced dermal granulomatous hypersensitivity with the phase I WCV by using an experimental guinea pig model for C. burnetii. In this model, phase I WCV induced epithelioid cell infiltration, multinucleated giant cells, leukocytoclasis, and collagen deposition (2) . When CMRV was tested, it induced delayed-type hypersensitivity without granuloma formation and elicitation of antigenic lymphocyte proliferation activity (4) . Inferentially, these studies suggest that interacting components extracted by chloroform-methanol from phase I WCV may be considered as virulence factors which have adjuvant-active properties associated with anti-phase I response (Table 2) , deleterious tissue reactions represented by hepatosplenomegaly and liver necrosis (32) , induction of lymphocyte hyporesponsiveness and negative modulation (9) , and elicitation of granulomatous hypersensitivity in guinea pigs (4) .
Activities associated with phase I WCV may be somewhat analogous to the clinical and experimentally induced immunologic unresponsiveness described for other microorga- nisms (6, 28) . C. burnetii can modulate the immune response in several ways, including potentiation (14-16) and immunosuppression (9, 17) . Adverse properties of phase I C. burnetii may be similar to the biological activities of cell wall components of the mycobacteria (6, 7, 24) . The immunological unresponsiveness elicited by the mycobacterial products (6, 24) has been correlated with pathogenesis and especially with the ability of mycobacteria to evade the action of lysosomal enzymes. A key antimicrobicidal mechanism of C. burnetii is the adaptation of this obligately intracellular acidophilic bacterium (12) to replicate in the phagolysosome of immune or nonimmune host cells (5) .
Induction of immunoregulatory mechanisms to function in pathologic and suppressor modes may be initiated by the composition of the antigenic mass. Unique determinants present on phase I C. burnetii may induce specific suppressor cell functions that regulate the activity of lymphocytes to mitogens and antigens. No unique epitopes of C. burnetii which induce this immunological unresponsiveness have been identified by others. We show here that phase I C. burnetii induce immunological hyporesponsiveness and negative modulation of lymphocytes to mitogens and recall antigens. The extraction or disassociation of a complex from phase I C. burnetii by chloroform-methanol extraction yields an efficacious CMRV. Reconstitution of CMRV with CME restored the pathogenic nature of the CMRV to that of the phase I WCV. The CMRV contains proteins, phosphorus, neutral sugars, KDO-like compounds, fatty acids, and phase I lipopolysaccharide (LPSI) (1) . Although LPSI is important in the development of immunity (5; unpublished data), it is also considered to be a major determinant of the virulence of phase I C. burnetii. However, we show that the presence of LPSI in CMRV does not induce the deleterious reactions and suppression of in vitro lymphocyte proliferation. In a previous study, phase II WCV or infection did not induce lesions or suppression of in vitro lymphocyte proliferation (9) . It appears, therefore, that some other components of phase I C. burnetii are important determinants of the induction of immunopathological reactions; however, adverse reactions cannot be assigned solely to LPSI. These results indicate that certain phase I cells contain specific determinants of a suppressive complex which are diassociated by chloroform-methanol extraction. The CME contains specific or nonspecific hydrophobic components which are required to reconstitute with phase I CMRV to produce an active suppressive complex. Studies are underway to fractionate the CMRV and CME so that the interacting molecules can be purified and characterized as to immunogenicity and pathogenicity.
